Our news

• Announce: Novamedica on BIO 2013: Spotlight On The BRICs. Russia

  19 April 2013

  

  BIO International Convention (BIO-2013). Chicago, USA. Special session «Spotlight on the BRICs: Russia» Monday, Apr 22, 2013 

• NovaMedica launches its website using a new domain name www.novamedica.com

  18 April 2013

  Pharmaceutical company NovaMedica announces the launch of its website using a new domain name www.novamedica.com. One of the main reasons for moving the website to a new domain that would be more consistent with the сompany’s name is our desire to offer our current and potential partners an easier access to the information about the сompany.

• Regulatory changes in the procedure of expert review and registration of new drugs are needed towards localization of innovative pharmaceutical products in Russia – Vladimir Gurdus

  02 April 2013

  

  "To improve quality and safety of new drugs to be introduced to the Russian market and for localization of innovative pharmaceutical products in the country, the expert review and registration of such products require procedural changes”, - Vladimir Gurdus, CEO of D-Pharma, LLC, a managing company of “RusnanoMedInvest” and “NovaMedica” projects stated at the Conference “State regulation and the Russian pharmaceutical industry 2013: continuation of the dialogue”.

• Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry – Mikhail Getman

  26 March 2013

  

  "Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry”, - said Mikhail Getman, VP for R&D and Regulatory Affairs of NovaMedica, LLC at the 1^st meeting of the Subcommittee for international cooperation in modernization and innovations in healthcare and pharmaceutical industry of the Russian Chamber of Commerce and Trade.

• RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals

  19 December 2012

  U.S. venture capital firm Domain Associates, Rusnano subsidiary RusnanoMedInvest (RMI) and a group of co-investors will invest a combined $93m in Marinus Pharmaceuticals, Inc., Lithera, Inc., and Regado Biosciences, Inc., all of which are developers of advanced pharmaceutical products.

• The production site of the Russian pharmaceutical company NovaMedica will be chosen in the 1st quarter of 2013

  13 November 2012

  The identification of location of the production site of a new pharmaceutical company NovaMedica, a joint enterprise betweenthe Russian high-technology investment fund RUSNANO and the American venture healthcare fund Domain Associates will be chosen at the end of the first quarter of 2013.

• Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

  12 November 2012

  

  Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.

• Russian pharmaceutical company NovaMedica announces the opening of its US office

  12 November 2012

  NovaMedica, a company whose mission is commercializing highly innovative pharmaceutical products in Russia and the CIS, today announces the opening of its US office.

• Special autumn session for the pharmaceutical business leaders

  01 October 2012

  

  Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.

• Domain Associates & RUSNANO announce first joint investment

  24 July 2012

  

  Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm and RusnanoMedInvest (“RMI”, a subsidiary of RUSNANO) today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ).